Project
Personalized mRNA cancer vaccine made from each patient's tumor mutations, developed by Moderna and Merck under the codes mRNA-4157/V940.
Merck and Moderna are preparing to file their personalized mRNA melanoma vaccine after a Phase 3 trial showed it delayed recurrence. At the STAT Summit, executives said the next task is showing it works in other tumors, and that they must pick where to look first.
Reality
Merck and Moderna's mRNA vaccine intismeran autogene slowed the return and spread of melanoma when added to an existing treatment in a late-stage trial. One trial cannot say which other cancers the same approach can treat.
Reality
Intismeran autogene plus Keytruda beat Keytruda alone in resected melanoma. The market added roughly $35bn to Moderna on a result the companies described only in adjectives.
Perspective Coverage
6 publishersReality
Intismeran autogene met both primary endpoints in a 1,137-patient melanoma trial. Every dose is built from one tumour's sequence, which turns approval into a question about process, not product.
Perspective Coverage
3 publishersReality
The companies say intismeran plus Keytruda slowed melanoma's return after surgery in the first randomized Phase 3 test of neoantigen vaccines. No detailed data has been released.
Perspective Coverage
4 publishersReality
Merck and Moderna put out no efficacy figures. Illumina still rose 16% and PacBio 18%, because an approved per-patient therapy implies a sequencing run per patient.
Perspective Coverage
3 publishersReality
Hana Asset Management's medical AI fund led every ETF listed in South Korea last week, helped by a Morgan Stanley estimate that Medicare coverage could add $330m to $400m of annual revenue at its largest holding.
Reality
Intismeran autogene would arrive with a selection procedure where other drugs have a fixed molecule, and the outside expert STAT asked could not say what the software weighs. That makes the ranking code the hard part of any review.
Reality
Moderna and MSD's V940 hit both endpoints in adjuvant melanoma. The commercial consequence sits with Keytruda SC, whose conversion rate reached 10.6% in July.
Reality